Hsbc Holdings PLC Has $114.61 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

Hsbc Holdings PLC decreased its position in Hologic, Inc. (NASDAQ:HOLXFree Report) by 6.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 1,604,494 shares of the medical equipment provider’s stock after selling 116,845 shares during the period. Hsbc Holdings PLC’s holdings in Hologic were worth $114,607,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in HOLX. Victory Capital Management Inc. boosted its stake in shares of Hologic by 4.5% in the fourth quarter. Victory Capital Management Inc. now owns 5,055,048 shares of the medical equipment provider’s stock valued at $361,183,000 after buying an additional 216,958 shares during the period. Norges Bank bought a new stake in shares of Hologic in the fourth quarter valued at approximately $217,529,000. DekaBank Deutsche Girozentrale boosted its stake in shares of Hologic by 2.9% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 1,634,362 shares of the medical equipment provider’s stock valued at $115,586,000 after buying an additional 45,785 shares during the period. Nordea Investment Management AB boosted its stake in shares of Hologic by 4.5% in the third quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider’s stock valued at $113,077,000 after buying an additional 69,494 shares during the period. Finally, Earnest Partners LLC boosted its stake in shares of Hologic by 6.8% in the third quarter. Earnest Partners LLC now owns 1,451,994 shares of the medical equipment provider’s stock valued at $100,768,000 after buying an additional 92,658 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Down 0.3 %

NASDAQ HOLX traded down $0.19 on Monday, reaching $73.80. The company had a trading volume of 1,303,200 shares, compared to its average volume of 1,691,107. The firm has a market cap of $17.22 billion, a price-to-earnings ratio of 37.65, a P/E/G ratio of 2.46 and a beta of 1.01. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $82.45. The business has a 50 day moving average of $76.10 and a two-hundred day moving average of $73.93. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.97 and a quick ratio of 3.29.

Hologic (NASDAQ:HOLXGet Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.05. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 18.91% and a net margin of 11.78%. Hologic’s quarterly revenue was down .8% on a year-over-year basis. During the same period in the prior year, the business posted $1.06 earnings per share. Analysts forecast that Hologic, Inc. will post 4.08 EPS for the current year.

Wall Street Analyst Weigh In

HOLX has been the subject of several recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Friday, May 3rd. Evercore ISI upped their target price on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Argus upped their target price on Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. William Blair reiterated an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. Finally, UBS Group increased their price target on Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research note on Friday, February 2nd. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $85.60.

Read Our Latest Report on Hologic

Insider Activity at Hologic

In related news, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the sale, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the sale, the director now directly owns 1,572 shares in the company, valued at approximately $119,802.12. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The disclosure for this sale can be found here. 1.75% of the stock is currently owned by company insiders.

Hologic Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Featured Articles

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXFree Report).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.